Price | 1,365.00on 08-03-2021 | at 16:30:00
---|---|
Change | 13.50 1.00% |
Buy | 1,370.00 |
Sell | 1,369.00 |
Buy / Sell SN. Shares |
Last Trade: | Sell 11,398 at 1,361.404p |
Day's Volume: | 2,006,668 |
Last Close: | 1,351.50p |
Open: | 1,364.00p |
ISIN: | GB0009223206 |
Day's Range | 1,342.00p - 1,371.50p |
52wk Range: | 1,055.50p - 1,742.50p |
Market Capitalisation: | £11,997m |
VWAP: | 0.00p |
Shares in Issue: | 879m |
Sector: Health Care and Related Services
Listed in: FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 Low Yield
Recent Trades History Smith & Nephew (SN.) |
||||
Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
---|---|---|---|---|
Sell* | 11,398 | 1,361.404 | Ordinary | 17:56:43 - 08-Mar-21 |
Sell* | 638 | 1,368.329 | Ordinary | 17:58:44 - 08-Mar-21 |
Sell* | 25,000 | 1,345.02 | Ordinary | 17:39:10 - 08-Mar-21 |
Sell* | 241 | 1,351.279 | Ordinary | 17:37:19 - 08-Mar-21 |
Sell* | 5,461 | 1,357.569 | Ordinary | 17:29:02 - 08-Mar-21 |
Sell* | 15,364 | 1,363.406 | Ordinary | 17:29:02 - 08-Mar-21 |
Sell* | 2,162 | 1,359.97 | Ordinary | 17:29:02 - 08-Mar-21 |
Sell* | 256 | 1,351.278 | Ordinary | 17:36:23 - 08-Mar-21 |
Sell* | 321 | 1,350.041 | Ordinary | 17:33:52 - 08-Mar-21 |
Sell* | 50 | 1,351.282 | Ordinary | 17:33:52 - 08-Mar-21 |
Share Price History for Smith & Nephew |
|||||
Date | Open | High | Low | Close | |
---|---|---|---|---|---|
5th Mar 2021 (Fri) | 1,352.00 | 1,371.00 | 1,343.00 | 1,349.00 | |
4th Mar 2021 (Thu) | 1,358.50 | 1,371.00 | 1,340.00 | 1,353.00 | |
3rd Mar 2021 (Wed) | 1,405.50 | 1,407.00 | 1,348.00 | 1,366.50 | |
2nd Mar 2021 (Tue) | 1,388.50 | 1,402.00 | 1,377.50 | 1,389.75 | |
1st Mar 2021 (Mon) | 1,400.50 | 1,408.50 | 1,384.50 | 1,394.00 | |
26th Feb 2021 (Fri) | 1,396.00 | 1,419.00 | 1,380.00 | 1,406.00 | |
25th Feb 2021 (Thu) | 1,432.50 | 1,440.00 | 1,401.50 | 1,437.75 | |
24th Feb 2021 (Wed) | 1,403.50 | 1,438.50 | 1,398.00 | 1,408.25 | |
23rd Feb 2021 (Tue) | 1,413.50 | 1,429.50 | 1,386.50 | 1,412.75 | |
22nd Feb 2021 (Mon) | 1,409.50 | 1,440.50 | 1,401.00 | 1,412.75 | |
19th Feb 2021 (Fri) | 1,474.00 | 1,515.50 | 1,470.50 | 1,480.00 | |
18th Feb 2021 (Thu) | 1,475.00 | 1,538.50 | 1,440.00 | 1,567.75 | |
17th Feb 2021 (Wed) | 1,582.00 | 1,592.00 | 1,561.50 | 1,567.75 | |
16th Feb 2021 (Tue) | 1,609.00 | 1,619.50 | 1,589.50 | 1,592.00 | |
15th Feb 2021 (Mon) | 1,570.00 | 1,606.50 | 1,568.00 | 1,605.50 | |
12th Feb 2021 (Fri) | 1,556.00 | 1,572.50 | 1,553.50 | 1,566.25 | |
11th Feb 2021 (Thu) | 1,554.50 | 1,573.50 | 1,548.50 | 1,560.75 | |
10th Feb 2021 (Wed) | 1,553.50 | 1,563.00 | 1,543.00 | 1,549.75 | |
9th Feb 2021 (Tue) | 1,540.50 | 1,551.00 | 1,535.50 | 1,541.50 |
Smith & Nephew are presently the UK's largest medical technology company and one of global significance in its specialised field. Established over 150 years ago, the company now operates in over 30 countries worldwide, with their headquarters still being in London, UK. Their main focus revolves around developing and promoting novel products to help physicians treat aging patients with endoscopy techniques, orthopaedic reconstruction, trauma and advanced wound management being at the forefront of their research. The company feel that the increasingly aging population equals a significant growth potential for the already established markets of orthopaedics, endoscopy and wound management around the world.
Today, Smith & Nephew have over 1000 products in their arsenal and generate worldwide sales of over 3.4 billion dollars. They further report that over the last 5 years their revenues have grown from around nineteen hundred million dollars to over thirty three hundred million dollars – a percentage increase of nearly 100%. This success has been helped along by the launch of a new range of ingenious wound dressing products in 2008 and the acquisition of the Swiss company Plus Orthopaedics Holdings AG in 2007. Smith & Nephew research, develop and manufacture a number of new orthopaedic and wound management products each year, many of which quickly become established products within the UK and the US. The share price of this major medtech company has stayed stable for a number of years and continues to rise as new products are launched.
News - Thursday, February 18, 2021
FTSE drops more than 1% after weak US data The FTSE 100 surrendered its gains f......
News - Thursday, February 18, 2021
The FTSE 100 saw losses deepen by lunchtime on Thursday as the positive sentimen......